key: cord-0703312-a21p3843
authors: Jin, Shengwei; An, Hui; Zhou, Tong; Li, Ting; Chen, Chengshui; Ying, Binyu; Xu, Zhangye; Li, Xiaokun; Li, Ming
title: Inflammation/coagulopathy/fibrinolysis: Dynamic indicators of COVID-19 progression in patients with moderate COVID-19 in Wenzhou, China
date: 2021-09-11
journal: Clin Immunol
DOI: 10.1016/j.clim.2021.108852
sha: 9d217339cc87512bd69c4abdbe2576806e0c234e
doc_id: 703312
cord_uid: a21p3843

BACKGROUND: Majority of coronavirus disease 2019 (COVID-19) non-survivors meet the criteria for disseminated intravascular coagulation (DIC). Although timely monitoring of clotting hemorrhagic development during the natural course of COVID-19 is critical for understanding pathogenesis, diagnosis, and treatment of the disease, however, limited data are available on the dynamic processes of inflammation/coagulopathy/fibrinolysis (ICF). METHODS: We monitored the dynamic progression of ICF in patients with moderate COVID-19. Out of 694 COVID-19 inpatients from 10 hospitals in Wenzhou, China, we selected 293 adult patients without comorbidities. These patients were divided into different daily cohorts according to the COVID-19 onset-time. Retrospective data were extracted from electronic medical records. RESULTS: The virus-induced damages to pre-hospitalization patients triggered two ICF fluctuations during the 14-day course of the disease. C-reactive protein (CRP), fibrinogen, and D-dimer levels increased and peaked at day 5 (D5) and D9 during the 1st and 2nd fluctuations, respectively. The ICF activities were higher during the 2nd fluctuation. Although twelve-day medication returned high CRP concentration to normal and blocked fibrinogen increase, the D-dimer levels remained high on 17 ± 2 and 23 ± 2 days of COVID-19 course. CONCLUSION: COVID-19 is linked with chronic DIC, which could be responsible for the progression of the disease. Understanding and monitoring ICF progression during COVID-19 can help clinicians in identifying the stage of the disease quickly and accurately, and administer suitable treatment.

The angiotensin-converting enzyme 2 (ACE2) is the critical receptor on cell membranes for mediating SARS-CoV-2 entry into host cells [5] . Endothelial cells and smooth muscle cells are rich in ACE2 receptors [6] , indicating that these cells could be the targets of the virus. In addition to lung injuries, vascular damage produced by viral infection could acutely increase the plasma C-reactive protein (CRP) concentration, which is the first acute-phase protein identified during tissue damage or inflammation. CRP induces several prothrombotic activities, including increase in the expression and activity of tissue factor (TF), decrease in the expression of TF pathway inhibitor [7] , activation of inflammation and blood coagulation, impairment of the endogenous fibrinolytic capacity, and stimulation or enhancement of platelet adhesiveness and responsiveness [8] . Epidemiological studies have revealed that CRP concentrations are associated with increased risk of venous thromboembolism (VTE) [9] . Clinically, D-dimer is extensively used for the diagnosis of VTE [10] . Healthy individuals have low serum D-dimer levels, which is a biomarker of fibrin formation and degradation. Although virus-induced overt-DIC has been recognized in COVID- In this study, 694 patients (consecutive) with confirmed COVID-19 admitted to 10 hospitals in Wenzhou City, Zhejiang Province, China from Jan 17, 2020 to Mar 20, 2020 were enrolled. The diagnosis of COVID-19 was made according to the World Health Organization [12] interim guidelines and confirmed using RNA detection of the SARS-CoV-2 in the clinical laboratory of the hospitals as described previously [13] . Patients with COVID-19 were stratified into mild (mild symptoms and no sign of pneumonia), moderate (pneumonia and oxygenation index >300 mmHg), and severe (pneumonia and oxygenation index <300 mmHg) patients. Exclusion criteria was as follows: all patients with comorbidities, smokers, age <18 or >65 years, and habits/conditions that may alter the clinical parameters during the natural progression of COVID-19. Data related to disease progression were obtained from medical records and from detailed interviews with patients. Patients without record of the onset-time of the first symptoms were classified as failed cases (n = 7).

To study the clinical profiles of CRP and coagulatory systems during the natural course of COVID-19, we included only moderate cases in the daily cohort. Two main J o u r n a l P r e -p r o o f reasons to exclude the mild and severe patients from the daily cohort studies were as follows: 1) following application of the exclusion criteria, the number of cases in these two groups was small, and 2) the clinical manifestations of either too mild or too severe could mask the true feature of the disease and may not be appropriate to demonstrate the dynamic profiles of CRP and coagulatory systems during the natural course of COVID-19.

According to the onset of the first symptoms before admission, the natural course of COVID-19 was studied every day. The daily distribution of cases is shown in Table 1 . Depending on the daily profile of CRP changes, we grouped the nearby days without statistically significant differences of CRP levels and categorized them into three groups (Table 2) : day 1-4 (D1-4, n = 123), day 5-7 (D5-7, n = 91), and day 8-14 (D8-14, n = 69). We also investigated the CRP and fibrinogen (FIB) parameters measured at the time of admission in mild patients (n = 10).

From electronic medical records, we collected epidemiological, demographic, clinical, laboratory, treatment, and outcome data by using a standardized data collection form.

Three physicians (CC, BY, and TL) and a researcher (SJ) checked all data and adjudicated any difference in interpretation among the three primary reviewers. 

According to data distribution, the results were given as the mean ± standard deviation, median (interquartile range, IQR), or number (percentage During the 14-day progression of COVID-19, the oxygenation index was within the normal range in all moderate patients. CRP level was higher on day 1 (D1) in the moderate patients (p<0.05) when compared to that in the mild patients, but this was not the case for FIB levels (Figs 1A and 1B). Daily analysis in the moderate cases revealed that a low fluctuation between day 1-7 (D1-7) was followed by a high fluctuation (D7-14) of serum CRP levels with peaks at D5 and D9 (p<0.01 and p<0.001, respectively, Table 1 ) (Fig 1C) . The daily changes in serum FIB levels appeared as the tooth-waveform overlapped on the main profile of increasing responses ( Fig 1D) . The two peaks of the tooth-waveform of FIB levels were at D5 and D9 (both p<0.001, Table 1 ). The serum CRP levels were positively correlated with FIB levels (r = 0.671, p<0.001, n = 238, Fig 1E) . D-dimer levels weakly reflected the dynamic changes in the FIB levels during D1-6. The small fluctuation occurred from D3-6 with a peak at D5 (p<0.01, Fig 1F) . From D6, D-dimer levels increased and reached a significantly high level at D9 (p<0.01 vs. D6), which were then maintained (p<0.01 at D10; both p<0.001 at D11-12 and D13-14 vs. D1, Table   1 ). The serum D-dimer levels were positively correlated with the FIB levels (r = 0.496, p<0.001, n = 232, Fig 1G) . The platelet counts were significantly lower at D3 (p<0.01) and D6 (p<0.05) than those at D1 (Table 1) . (Table 2) . Table 2 validates the findings presented in Table 2 Table 2 reveals two new features of the disease:

1) the incidence of diarrhea and fatigue occurred more often during the first thrombiforming period D5-7 (p<0.001) and 2) the markers of liver damage, serum total and direct bilirubin, showed abnormal levels (p<0.001 and p<0.05 respectively) in the second inflammatory/coagulatory period, indicating that digestive system damage had occurred. (Table 3 ) and blocked further increase in FIB levels, D-dimer and IBil levels remained significantly high on post-treatment day 6 (P6) and

P12 when compared to those on D1-4 (Table 3) . No overt-DIC in these patients was observed, as both PT and APTT did not show clinically significant changes (Table 3) .

Acute respiratory distress syndrome (ARDS) was not observed in these patients. 

Virus-induced overt-DIC has been observed in patients with COVID-19 [3, 4] . As DIC progresses rapidly, COVID-19 develops into a hypercoagulable status, which results in severe thrombi formations, thus, leaving no time for therapy [3] . Therefore, quick and accurate identification of the pre-DIC stage during COVID-19 is critical for clinicians to make correct diagnosis and administer treatment. However, the pre-DIC or the chronic DIC (CDIC) stage is difficult to identify. According to the medical can increase the expression and activity of TF, decrease TF pathway inhibitor levels, activate inflammation and blood coagulation, impair endogenous fibrinolytic capacity, and stimulate or enhance platelet adhesiveness and responsiveness [7] ; CRP concentrations are also associated with increased risk of VTE [8] . FIB can play overlapping roles in blood clotting, fibrinolysis, cellular and matrix interactions, inflammatory response, wound healing, and neoplasia [14] . Thus, elevated circulating CRP and FIB levels could act as significant risk indicators for the development or progression of the pre-DIC stage. We observed that the decrease in FIB levels at D6

and D10 was associated with a reduction in platelet counts, which is an indicator of thrombus formation. This finding was supported by a mild but significant elevation of a homolysis marker, IBil, at D7 and D11-12. Because red blood cells (RBCs) are pushed through the thrombi compromised tiny vessels in the microvasculature, hemolysis occurs and serum IBil increases [15] . Although COVID-19 in the initiating phase produces limited fibrin thrombi in arterioles and capillaries, it could result in ischemia and multiorgan damage. This would initiate strong inflammation, aggravate tissue damage, and lead to a stronger responsive phase-the amplifying phase.

In the amplifying phase, the CRP peak level at D9 was higher than that at D5;

both FIB and D-dimer levels were also higher and positively correlated. D-dimer levels were 3-fold higher at D13-14 than those at D5. D-dimers are produced from intravascular thrombi and clots that have recently been formed [15, 16] . Hence, the 3fold higher D-dimer levels indicate 3-fold higher thrombosis in the amplifying phase.

In both phases, both PT and APTT were only slightly prolonged (or normal) in the moderate patients (Tables 1-3 ). This usually occurs in CDIC that develops when patients are exposed to small amounts of thrombin [13] ; when the coagulation materials are consumed, the patient is partially able to compensate through their increased production. In this study, the platelet counts were only mildly altered, which is a typical manifestation of CDIC. Both endothelial cells and smooth muscle cells are rich in ACE2 receptors [5] , which could be SARS-CoV-2 targets. Therefore, the vasculitis caused by SARS-CoV-2 may be one of the factors leading to CDIC. SARS-CoV-2 spreads through the bloodstream and mainly lodges in the lungs, gastrointestinal tract, and heart. The median time for dyspnea at D7 (4-9) in severe patients calculated in a previous study [17] was consistent with the mild homolysis time (D7) in the moderate patients in our study. In addition, the incidence of diarrhea and fatigue occurred more often in the moderate patients during D5-7, which is consistent with the thrombi-forming time during the initial strike of the SARS-CoV-2.

These data indicate that some local tissues (lungs, digestive system, and muscles) may have thrombi formation during the first strike, which leads to tissue damage and a more severe second strike. During the second strike, the SARS-CoV-2 combined with the endogenous damages of the pre-DIC stage, initiates a double increase in CRP response, and both FIB and D-dimer responses were accumulative. The second thrombi-forming period was during D9-12 and obvious homolysis was observed around D11-12, which is consistent with time from illness onset to ARDS and time from illness onset to ICU admission in severe patients, respectively [17] .

J o u r n a l P r e -p r o o f Due to the absence of a gold standard for the diagnosis of DIC, the diagnostic rates of the DIC criteria cannot be properly assessed [18, 19] . Here, we show that the dynamic changes and significantly positive relationships of the triple-parameters (CRP/FIB, FIB/D-dimer) can improve the detection of the pre-DIC stage or the CDIC process during COVID-19 progression. CRP induces several prothrombotic activities [6, 7] . FIB can play overlapping roles in coagulatory and inflammatory responses [14] . D-dimer is a valuable marker of activation of coagulation and fibrinolysis [10] .

Serum D-dimer has been used for prognosis in 2009 Novel Influenza A (H1N1) [20] .

Thus, dynamic monitoring of serum CRP, FIB, and D-dimer levels in patients with COVID-19 would assist in timely diagnosis and treatment of the patients. 

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Endothelial cell infection and endotheliitis in COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and its implications for thrombosis and anticoagulation

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS letters

Activation of inflammation and coagulation after infusion of C-reactive protein in humans

Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond. Sub-cellular biochemistry

A Test in Context: D-Dimer

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Coronavirus disease 2019 (COVID-19): A literature review

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Fibrinogen and fibrin structure and functions

Disseminated Intravascular Coagulation

Value of D-dimer levels for the diagnosis of pulmonary embolism: An analysis of 32 cases with computed tomography pulmonary angiography. Experimental and therapeutic medicine

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prognostic accuracy of different disseminated intravascular coagulation criteria in critically ill adult patients: a protocol for a systematic review and meta-analysis

Diagnosis of overt and non-overt disseminated intravascular coagulation: A survey among experts and a call for action from the ISTH

Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)

(to TL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder had no role in this study design, data collection, analysis and interpretation, or writing of the report. The corresponding authors (ML and XL) had full access to all the data in the study and had final responsibility for the decision to submit for publication.

ML and XL contributed equally to this paper and are joint corresponding authors. SJ and HA are joint first authors. The corresponding and first authors conceived and designed the study. ML and XL had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. ML, SJ, and HA drafted the paper. ML, SJ, HA, ZX, and TZ performed data analysis, and J o u r n a l P r e -p r o o f Journal Pre-proof all authors critically revised the manuscript for important intellectual content and gave final approval for the version to be published. TL, CC, and BY collected the data. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.Competing interests: None declared.